Similarly, in the DFCI cohort, the prevalence of TP53 mutations was 57.7% in BRAF and PIK3CA wild type cancers and 39.2–43.5% in cancers with either or both BRAF and PIK3CA mutated (Fisher’s exact test p < 0.0001, Figure 2B). This evidence concerns the gene BRAF and cancer.